

Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes

Rene A Oliveros, MD, FACC,¹ Son V Pham, MD, FACC,² Steven R Bailey, MD, FACC³ and Robert J Chilton, DO, FACC⁴

1. Assistant Professor and Director, Cardiac Care Unit, Audie L Murphy VA Hospital, University of Texas Health Science Center at San Antonio;

2. Assistant Professor and Chief of Cardiology, Audie L Murphy VA Hospital, University of Texas Health Science Center at San Antonio;

3. Professor and Chief, Division of Cardiology, University of Texas Health Science Center at San Antonio; 4. Professor and Director, Catherization Lab, Audie L Murphy VA Hospital, University of Texas Health Science Center at San Antonio, San Antonio, Texas, US

Citation: *US Endocrinology*, 2014; 10(2):i [online only]

Erratum to: *US Endocrinology*, 2014;10(1):8–15

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section of the above-mentioned paper: Rene A Oliveros, Son V Pham, Steven R Bailey and Robert J Chilton have no conflicts of interest to declare.